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A B S T R A C T   
Background: Preeclampsia, preterm birth and low birth weight represent key contributing factors to perinatal 
morbidity and mortality. Pregnancies complicated by type 1 and type 2 diabetes are at increased risk of these 
complications, which are purported to be largely attributed to placental dysfunction. Studies investigating a 
potential role for aspirin therapy in optimizing perinatal outcome have consistently failed to demonstrate a 
benefit among women with pre-existing diabetes, and yet widespread aspirin administration has become com-
mon practice in many centres. This study seeks to examine the effect of aspirin therapy, administered from the 
first trimester until 36 weeks gestation, on perinatal outcome in women with established pre-pregnancy diabetes. 
Our hypothesis is that aspirin therapy will reduce complications mediated by placental dysfunction, and improve 
perinatal outcomes. 
Methods: This phase III double-blinded, placebo-controlled randomized clinical trial will be conducted in seven 
tertiary-level perinatology centres in Ireland. Consenting participants who meet all eligibility criteria will be 
allocated randomly to either aspirin 150 mg once daily or matching placebo, commenced between 11  0 and 
13  6 weeks. Allocation will take place electronically using software by Clininfo with randomization 
tables provided by the trial biostatistician. The primary outcome will be a composite clinical measure of 
placental dysfunction (preeclampsia, preterm birth before 34 weeks, birthweight below the 10th centile or 
perinatal mortality). This trial has been set up such that it is parallel in design and is a superiority study. No 
participants have been recruited yet. The trial has been registered with Eudra Clinical Trials - EudraCT Number 
2018-000770-29. Funding for this trial was granted by the Health research Board (HRB) 1/9/2017(DIFA-2017- 
026). 
Discussion: Aspirin therapy has been investigated for the prevention of preeclampsia owing to its reduction on 
thromboxane production. Previous studies have failed to demonstrate a beneficial effect of aspirin on perinatal 
outcome amongst women with type I or type II diabetes. It is plausible that the failure to observe benefit to date, 
among the limited aspirin studies that have included participants with diabetes, may be a consequence of aspirin 
initiation too late in pregnancy to exert any effect on placentation. We believe that if aspirin is to be used for the 
prevention of placental dysfunction, it must be initiated before the second active phase of trophoblast invasion, 
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which takes place from 14 weeks’ gestation onwards. No randomized trials investigating the role of aspirin in 
prevention of preeclampsia in pregnancies complicated by diabetes have previously initiated treatment in the 
first trimester, the gestational period at which it is most likely to exert an effect on placentation.   
1. Background 
Pregnant women with pre-existing diabetes are at high-risk for 
evolution of placenta-mediated complications. Rates of preeclampsia 
within this group are approximately 20% [1,2]. The National Institute 
for Health and Care Excellence (NICE) has issued guidance on the pre-
vention of hypertension in pregnancy that includes a recommendation 
that women deemed to be at high risk for hypertension in pregnancy, 
such as pregnant women with pre-existing diabetes, be considered for 
aspirin therapy after 12 weeks gestation. However international guid-
ance is at odds with this such that the Royal College of Obstetricians and 
Gynaecologists (RCOG), American College of Obstetricians and Gyne-
cologists (ACOG) and Health Service Executive (HSE) do not recom-
mend it. 
Pre-existing nephropathy places a woman at particularly high risk 
for superimposed preeclampsia and for fetal growth restriction. Whether 
sub-threshold degrees of microvascular disease, as evidenced by 
microalbuminuria in early gestation, may confer a heightened risk of 
preeclampsia, is unclear. However whether aspirin therapy may benefit 
this subgroup with microalbuminuria has not been studied previously. 
The combination of diabetes and preeclampsia places the pregnancy 
at heightened risk for hypoxia and stillbirth. Placental dysfunction, due 
to disordered early placental development, is central to the disease 
process [1]. Widespread endothelial dysfunction is the hallmark of 
preeclampsia, and results in vasoconstriction, ischaemia and increased 
vascular permeability [2]. While not all adverse perinatal outcomes in 
diabetes are attributed to placental dysfunction, any therapy that offers 
the potential to optimise placentation in this group deserves close 
attention. 
Aspirin has been investigated for the prevention of preeclampsia 
owing to its reduction on thromboxane production. An imbalance be-
tween prostacyclin and thromboxane plays a key role in the develop-
ment of PET and is believed to result from shallow placental invasion 
and ischaemia that occur shortly after implantation, very early in the 
first trimester of pregnancy [3]. 
Studies on the role of aspirin in preventing preeclampsia have pro-
duced conflicting results. Initially studies showed a reduced risk [4–6], 
but larger studies failed to show any benefit [7–9]. A metaanalysis based 
on 27 trials found aspirin reduced the incidence by 10% [10], but it’s 
authors felt this was too modest to warrant implementation. Of note, 
among the participants included that had diabetes pre-pregnancy, none 
were recruited before 16 weeks, so may not have shown the benefit of 
aspirin. 
A large multicentre Maternal-Fetal Medicine Units (MFMU) network 
study investigated the role of aspirin in preventing preeclampsia and 
included a subgroup of pregnant women with pre-existing diabetes [2], 
however they were all recruited in the second trimester. If aspirin is to be 
used for the prevention of placental dysfunction, theoretically it must be 
initiated before the second active phase of trophoblast invasion, which 
takes place from 14 weeks’ gestation onwards. 
The dose of aspirin used in different trials has varied from 50 to 
150 mg. For some women, particularly those with obesity as well as type 
2 diabetes, the commonly used 60 mg dose may be too low to produce an 
adequate response as evidenced by recent work done which indicated 
20% of participants in Ireland have an inadequate response to aspirin, as 
evidenced by thromboxane levels. Their analyses suggested that age, 
hypertension and weight were the main risk factors to being a non- 
responder [11]. 
2. Methods 
The aim of this study is to answer the clinical question of whether 
low-dose antiplatelet therapy (150 mg aspirin) in pregnancy may carry 
the potential to optimise pregnancy outcome in pregnant women with 
pre-existing diabetes. Our hypothesis is that aspirin therapy will reduce 
complications mediated by placental dysfunction, and improve perinatal 
outcomes. 
This is a phase III prospective randomized double-blinded placebo- 
controlled trial of daily low-dose aspirin 150 mg initiated between 11 
and 13  6 weeks and continued until 36 weeks of gestation. The trial 
will be multicentre in seven maternity units in Ireland. This is a parallel 
study with an allocation ratio 1:1. 
This trial was designed according to Consolidated Standards of 
Reporting Trials (CONSORT) guidelines. 
Potential participants are pregnant women that have been diagnosed 
with diabetes at least 6 months prior to pregnancy. Potential partici-
pants will be identified at antenatal clinics and, if they provide informed 
consent, will be invited to take part in the trial if they meet all inclusion 
criteria and none of the exclusion criteria. 
2.1. Inclusion criteria  
 Ability to comprehend the Participant Information Leaflet and to 
provide signed and dated evidence of informed consent.  
 Willing to comply with all study procedures and be available for the 
duration of the study  
 Female, age >18 years  
 Singleton pregnancy, ongoing at 11–13  6 weeks’ gestation  
 Diagnosed with diabetes at least 6 months prior to pregnancy  
 Fulfillment of each criterion must be clearly evidenced (in lab reports 
or correspondence) and/or documented in the medical records. 
2.2. Exclusion criteria 
 Aspirin hypersensitivity (prior bronchospasm/urticarial/angioe-
dema with aspirin)  
 Active or recurrent peptic ulceration (2 or more distinct episodes of 
proven ulceration or bleeding)  
 Known bleeding diathesis (hypothrombinaemia, haemophilia, von 
Willebrands’ disease)  
 Multifetal gestation  
 Breastfeeding  
 Severe early-onset preeclampsia in a previous pregnancy  
 Participant already on aspirin at the time of screening  
 Established chronic kidney disease (progressive loss of renal function 
of at least 3 months’ duration)  
 Proteinuria (24-h urinary protein 300g or greater (or spot urinary 
protein/creatinine ratio >0.3) in the first trimester)  
 Chronic hypertension (antihypertensive therapy in first trimester)  
 Inability to speak or read English  
 SSRI use (current or within last 7 days)  
 Inflammatory bowel disease (Crohn’s disease or Ulcerative colitis) 
 Use of any other investigational medicinal product within the pre-
vious 30 days  
 The presence of any illness or condition that might interfere with the 
participant’s ability to comply with the study procedures  
 Hyperemesis 
Following the above, women will be asked to consent in antenatal 
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clinic by the chief investigator, then enrolled and allocated randomly 
using the software package Clininfo by either the chief investigator or 
sub-investigator. No personal information will be collected, participants 
will be allocated a study number and anonymous otherwise. All data 
collected will be entered into the eCRF. 
Women will be allocated randomly to one of two study groups: low- 
dose aspirin (150 mg) or placebo once daily from the first trimester 
(initiated between 11  0 weeks and 13  6 weeks of gestation) until 36 
weeks or sooner if early delivery is planned. The schedule of assessments 
is as follows: Table 1. 
2.2.1. Randomization 
Randomization of each study participant will utilize random block 
sizes (2, 4 and 6) with equal allocation to the study treatment arms (1:1 
ratio) within each participating centre. Consequently, the final overall 
randomized population may not be precisely 1:1. The randomization 
seed will be stored in the trial master file for the potential situation 
where the randomization list is required to be re-generated or expanded. 
2.2.2. Unblinding 
The study code should only be broken for valid medical or safety 
reasons e.g. in the case of a severe adverse event where it is necessary for 
the Investigator or treating health care professional to know which 
treatment the participant is receiving before the participant can be 
treated. Subject always to clinical need, where possible, members of the 
research team should remain blinded. 
2.2.3. IMP and placebo 
The IMP to be used in this trial: Tromalyt® 150 mg prolong release 
capsule for oral ingestion. The capsule contains 150 mg of anti-platelet 
agent acetylsalicylic acid, maize starch and Sucrose 20:80. The 
capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethyl-
cellulose and Triacetin. The capsule is made with gelatine, erythrosine, 
quinoline yellow, titanium dioxide. Tromalyt® is trademark of Meda 
Pharma SL (Reg 59.210). 
Placebos to be used are hard gelatine capsules (Sanitatis®) for par-
ticipants randomized to the placebo arm. These capsules are externally 
identical to Tromalyt capsule. The capsules contain 198 mg microcrys-
talline cellulose and 2 mg of magnesium stearate (Sanitatis®). 
Following enrolment participants will be randomly allocated to 
either aspirin of placebo and baseline investigations will be performed. 
4-Weekly study visits will be scheduled until 32 weeks gestation, a 34 
and 36 week visit, and then weekly reviews until delivery. 
Participants will be instructed to take the Investigational Medicinal 
Product (IMP) once daily at the same time with water. Participants will 
be provided with a diary card and instructed to complete the diary each 
day following administration of medication. Both the diary and the 
returned IMP will be checked by the Chief Investigator/Principal 
Investigator (CI/PI) or designee. Any discrepancies which suggest non- 
compliance will be discussed with the participant during the visit. 
Ongoing non-compliance may result in the participant being withdrawn 
from the trial. 
2.2.4. Data collection 
Data will contemporaneously be collected and inputted to an elec-
tronic case report form (CRF) and collected in a central database. 
The primary outcome is to investigate the effect of aspirin therapy 
initiated in the first trimester of pregnancy in women with pre-existing l 
type I or type II diabetes on a composite clinical outcome of placental 
dysfunction (preeclampsia, preterm birth less than 34 weeks, birth 
weight below the 10th centile or perinatal mortality). 
Secondary outcomes include will be observational studies and 
include: 
Differences between the intervention and control groups will be 
measured for the following parameters of neonatal morbidity:  
 Gestational age at delivery  
 Birth weight  
 Neonatal Intensive Care Unit (NICU) admission  
 Respiratory morbidity  
 Apgar score <7 at 5 min  
 Umbilical artery acidosis at birth (cord pH < 7.2)  
 Interventricular haemorrhage  
 Culture-proven sepsis  
 Necrotising enterocolitis  
 Hypoxic ischaemic encephalopathy 
Differences between the aspirin and control groups will be measured 
for maternal outcomes not directly related to primary outcome, 
including:  
 Mode of delivery  
 Haemorrhage  
 Sepsis 
The effect of 150 mg aspirin initiated in the first trimester of diabetes 
pregnancy on microalbuminuria will be evaluated. 
Platelet function testing: 
Platelet function testing will be performed on study participants at 
the Rotunda hospital only at 5 time points (pre-treatment, 20, 28 and 34 
weeks’ gestation and 3–5 days postpartum). 
Dynamic platelet function testing will allow the following aspects of 
antiplatelet therapy in pregnancy to be studied: 
2.3. Assessment of participant compliance with the study medication in 
this subgroup 
Evaluation of dynamic changes that may be observed in platelet 
aggregation with respect to participant-specific variables that may affect 
platelet biology, such as body mass index (BMI), age, concurrent illness 
or concomitant medication. 
Power analysis is based upon the assumptions that pre-eclampsia has 
an incidence of approximately 20% in the study population, and that the 
incidence of preterm delivery before 34 weeks is 4%, birth weight below 
the 10th centile is 9% and perinatal mortality 3%. Given that outcomes 
may overlap or co-occur, we assume the baseline rate for the composite 
outcome of placental dysfunction to be 30%, preeclampsia incidence 
plus approximately 50% of the remaining outcome rates. A sample size 
of 283 participants in each arm of the study would be required to 
demonstrate a 35% reduction in the composite clinical measure of 
placental dysfunction with 80% power (two-sided type I error 0.05). 
We expect to enrol 600 participants in total to allow for drop out and 
loss to follow-up. Recruitment is expected to take 24 months with each 
participant enrolled for 36 weeks (30 weeks on the trial medication and 
6 weeks postnatal follow up). 
Randomization, data management, data quality checks and statisti-
cal analysis will be performed by the trial biostatistician, Patrick Dicker 
(Biostatistician, Royal College of Surgeons in Ireland (RCSI)). The 
database will be anonymized, encrypted and stored in accordance with 
data protection law. 
All demographics and pregnancy characteristics will be presented 
according to randomized treatment without formal statistical compari-
sons. Continuous data will be presented using means, standard de-
viations, minima, maxima, medians and/or inter-quartile ranges, as 
appropriate. Frequency tabulations for categorical (nominal and 
ordinal) data will be presented. Patient disposition will be tabulated and 
presented as a consort flow diagram. 
2.3.1. Primary outcome analysis 
Randomization, data management, data quality checks and statisti-
cal analysis will be performed by the trial biostatistician, Patrick Dicker 
(Biostatistician, RCSI). The database will be anonymized, encrypted and 
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Table 1 
Schedule of assessments.   
Recruitment Follow Up 
Visit # 1 2 3 4 5 6 7 8 9–14 Delivery Follow-up 
Visit Type Screening 
period 
Baseline Monthly visit Monthly visit Monthly visit Monthly 
visits 
Monthly 
visits 
2-weekly Weekly visit End of study visit Follow-up visit 
Visit schedule Day 
  28 to 0 
Day 0 Gestation 
16weeks  7 
days 
Gestation 20 
weeks  7 
days 
Gestation 24 
weeks  7 
days 
Gestation 28 
weeks  7 
days 
Gestation 32 
weeks  7 
days 
Gestation 34 
weeks  7 
days 
Gestation 
36–40 
weeks  4 
days 
2Delivery  max 5 
days 
36 weeks 
postpartum  2 
weeks 
Informed Consent X           
Eligibility determination: medical & 
obstetric history review/medication 
review/pregnancy viability 
(ultrasound), urinary PCR/24-h 
quantitation/English proficiency 
X 1X          
Physical exam: weight; otherwise 
symptom driven 
X X X X X X X X X X 
FBC, liver profile, serum urea and 
creatinine 
X          
Vital Signs: BP/MAP X X X X X X X X X X X 
Dipstick urinalysis for proteinuria X X X X X X X X X   
Concomitant Medication review X X X X X X X X X X X 
Urinary PCR/24-h quantitation [4] X  X  X  X  X X X 
Platelet function assay (sub-study) [5]  X  X  X  X  X  
Fetal ultrasound: growth, UAD, AFI    X  X   X (36or37)   
Randomization  X          
IMP dispensing (36 tabs)*  X X X X X X     
Medication compliance review (pill 
count)*   
X X X X X X    
Adverse Events review   X X X X X X X X X 
Neonatal outcome review (birthweight, NICU admission, respiratory morbidity: need for O2 support, congenital anomaly, and adverse neonatal outcome)   X X  
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stored in accordance with data protection law. 
Four populations will be described and utilized in the statistical 
analyses:  
a. All Randomized  
b. Intention-to-treat (ITT): All randomized having a composite outcome 
measure  
c. Safety Population: All randomized who received at least one dose of 
study medication 
d. Per-protocol (PP): ITT population excluding major protocol viola-
tions and non-compliance with study treatment 
Prior to last-patient last-visit an expanded Statistical Analysis Plan 
will be approved by the Trial Steering Committee. 
As per the baseline data, all data collected post-randomization will 
be summarized using descriptive statistics. Major protocol violations 
will be listed individually. Safety data (adverse events) will be described 
in the safety population. Clinical outcomes (primary and secondary) will 
be described in the ITT and PP populations. 
The primary study outcome variable of placental dysfunction will be 
analyzed using logistic regression with randomized treatment group as a 
factor (ITT analysis). 
The 5% level of significance and 95% Confidence Interval will be 
used to determine the statistical significance of risk (odds-ratio). 
The software SAS version 9.4 will be used for data screening, query 
resolution and statistical analysis. 
Secondary outcome analysis: 
Formal secondary outcome analysis (hypothesis tests) will not be 
performed. 
No interim analyses will occur. Recommendations for premature 
termination of the trial will be described under the terms of the Data 
Safety and Monitoring Board (DSMB). 
After the last-participant-last-visit and resolution of data queries 
(database-lock), the code break of the randomization will be performed. 
Adverse events (AEs): 
All AEs occurring during the study observed by the investigator or 
reported by the subject, whether or not attributed to the study medi-
cation, will be recorded on the CRF. 
The following information will be recorded: description, date of 
onset and end date, severity, assessment of relatedness to the study 
medication, other suspect medication or device and action taken and 
outcome. Follow-up information should be provided as necessary. 
All AEs will be recorded in the medical records and CRF following 
consent. Clinically significant abnormalities in the results of objective 
tests (e.g. laboratory variables, fetal ultrasound abnormalities) will also 
be recorded as AEs. If the results are not expected as part of disease or 
IMP, these will also be recorded as unexpected. All AEs will be recorded 
with clinical symptoms and accompanied with a simple, brief descrip-
tion of the event, including dates as appropriate. 
All AEs will be captured up to 6 weeks postpartum. 
Certain adverse events are considered to constitute expected 
pregnancy-related symptoms/clinical signs that will not be recorded in 
the CRF, nor in the AE log. 
3. Discussion 
3.1. Assessment of compliance 
The percentage of noncompliance acceptable for participant to 
continue on the trial is as follows: <80% compliance equates to partic-
ipant withdrawal (this includes compliance with IMP and study pro-
cedures i.e. visit window, refusal of study specific assessments). 
Percentage of IMP compliance acceptable for participant to continue 
on the trial is 80% or greater. 
Noncompliance with the protocol study procedures will be docu-
mented by the investigator and reported to the Sponsor as agreed. 
Persistent noncompliance may lead the participant to be withdrawn 
from the study. 
3.2. Limitations 
As described above regarding participant compliance, if a participant 
has not taken at least 80% of the trial medication or not attended at least 
80% of the scheduled visits, they will be excluded from the trial. 
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